Search Within

Heather Jolie Landau

  1. "Master of Science in Clinical and Translational Cancer Research "
Formats
  1. Meeting Abstract (27)
  2. Journal Article (10)
  3. Research Letter (1)
Groups
  1. Bone Marrow Transplant (38)
  2. CTCR Scholars (38)
  3. Center for Hematologic Malignancies (38)
  4. Department of Medicine (38)
  5. Hematologic Malignancies, Division of (38)
  6. MSK Grad Students (38)

More Groups

People
  1. Sergio Giralt (37)
  2. Parastoo Dahi (32)
  3. Gunjan Shah (29)
  4. David Chung (28)
  5. Michael Scordo (24)
  6. Sean Devlin (20)

More People

Years
  1. 2023 (6)
  2. 2022 (3)
  3. 2021 (3)
  4. 2020 (9)
  5. 2019 (7)
  6. 2018 (4)

More Years

Publications
  1. Biology of Blood and Marrow Transplantation (14)
  2. Blood (12)
  3. Clinical Lymphoma, Myeloma and Leukemia (4)
  4. Annals of Oncology (1)
  5. Blood Advances (1)
  6. Bone Marrow Transplantation (1)

More Publications

Publishers
  1. Elsevier Inc. (19)
  2. American Society of Hematology (13)
  3. American Association for the Advancement of Science (1)
  4. American Society for Clinical Investigation (1)
  5. Cell Press (1)
  6. John Wiley & Sons (1)

More Publishers

Results (38)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Feasibility and toxicity of Pharmacokinetic (PK)-directed dosing of Evomela® (propylene glycol free melphalan, PGF-MEL) for multiple myeloma (MM) and AL amyloidosis (AL) patients undergoing autologous hematopoietic stem cell transplant (AHCT)
    Meeting Abstract

    Shah, G. L.; Lin, A.; Schofield, R.; Sarubbi, C.; Preston, E. V.; Devlin, S. M.; Bhatt, V.; Harnicar, S.; Hoover, E.; Chung, D. J.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Pharmacokinetics and toxicities after Evomela® (propylene glycol free melphalan) with hematopoietic stem cell transplant (HCT) for multiple myeloma (MM), AL amyloidosis (AL), lymphoma, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS)
    Meeting Abstract

    Shah, G. L.; Landau, H.; Sarubbi, C.; Schofield, R.; Lin, A.; Bhatt, V.; Harnicar, S.; Devlin, S. M.; Castro-Malaspina, H.; Chung, D. J.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • A phase 1/2 trial of carfilzomib + high dose melphalan conditioning for auto-HCT followed by carfilzomib maintenance for patients with relapsed multiple myeloma
    Meeting Abstract

    Costa, L. J.; Landau, H.; Chhabra, S.; Hari, P.; Innis-Shelton, R.; Saad, A.; Salzman, D.; Hamadani, M.; Tamari, R.; Williams, L.; more...
    Biology of Blood and Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Feasibility, tolerability, and patient-reported outcomes with pharmacokinetic (PK)-directed dosing of Evomela (propylene glycol free melphalan) for multiple myeloma and AL amyloidosis patients undergoing autologous hematopoietic stem cell transplant (AHCT)
    Meeting Abstract

    Shah, G. L.; Lin, A.; Schofield, R.; Sarubbi, C.; Preston, E. V.; Devlin, S. M.; Bhatt, V.; Harnicar, S. J.; Hoover, E.; Chung, D. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Pharmacokinetics and toxicities after Evomela® (propylene glycol free melphalan) with autologous hematopoietic stem cell transplant (AHCT) for multiple myeloma and AL amyloidosis
    Meeting Abstract

    Shah, G. L.; Landau, H.; Sarubbi, C.; Schofield, R.; Lin, A.; Bhatt, V.; Harnicar, S. J.; Devlin, S. M.; Chung, D. J.; Dahi, P. B.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Carfilzomib plus high dose melphalan conditioning prior to autologous hematopoietic cell transplantation followed by carfilzomib maintenance in patients with relapsed multiple myeloma
    Meeting Abstract

    Costa, L. J.; Landau, H.; Chhabra, S.; Hari, P.; Salzman, D.; Saad, A.; Innis-Shelton, R.; Hamadani, M.; Tamari, R.; Godby, K. N.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Low dose unfractionated heparin (UFH) prophylaxis is a feasible strategy for the prevention of hepatic sinusoidal obstruction syndrome (SOS) after myeloablative adult allogeneic hematopoietic stem cell transplantation (HSCT)
    Meeting Abstract

    Bhatt, V.; Palazzo, M.; Kilroy, K.; Hilden, P.; Devlin, S. M.; Maloy, M.; Barker, J. N.; Castro-Malaspina, H.; Chung, D. J.; Dahi, P.; more...
    Biology of Blood and Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • Low dose unfractionated heparin (UFH) prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome (SOS) in adult allogeneic stem cell transplant (HSCT) recipients
    Meeting Abstract

    Bhatt, V.; Palazzo, M.; Kilroy, K.; Hilden, P.; Maloy, M.; Barker, J. N.; Castro-Malaspina, H. R.; Chung, D. J.; Dahi, P. B.; Hsu, K. C.; more...
    Blood (2015)

    Fulltext@MSK | Save